In the News

Connect with us

Stay Informed.
Get the latest news and updates on MSK’s cancer care and research breakthroughs sent straight to your inbox with our e-newsletters.
Newsletter Sign Up
501 News Items found
Illustration of breast encompassing blue normal cells and red cancer cells.
Finding
A Missing Link Revealed: Researchers Gain Insight into Breast Cancer Drug Resistance

Researchers find an epigenetic role in how breast cancer tumors develop resistance to treatment.
People milling about at the 2019 ASCO meeting
Roundup
Highlights from ASCO 2019: A Low-Fat Diet and Breast Cancer Risk, Targeted Therapy for Salivary Gland Tumors, and More

Read about a few of the MSK studies being presented at the 2019 American Society of Clinical Oncology's annual meeting.
Christina and Kevin walk down stairs. Christina is wearing a blue dress and carrying a bouquet. Kevin is wearing a tuxedo.
FDA Approves New Treatment for Triple-Negative Breast Cancer

The FDA has approved the targeted therapy datopotamab deruxtecan (Datroway® or Dato-DXd) for triple-negative breast cancer based on clinical research led by MSK.
Cartoon of different-color heads with speaker and thought bubbles above them.
Feature
What You Should Know about Five Common Cancers

Even the most common cancers have aspects that are not fully grasped by the public.
an MSK researcher looks through a microscope
MSK Research Highlights, October 9, 2026

New MSK research uncovers an unknown role for immune cells in fueling triple-negative breast cancer; identifies a new strategy for fighting leptomeningeal metastases; finds trastuzumab deruxtecan shows enhanced benefit for patients with ERBB2 mutations in breast cancer; shows tumor DNA insights can help guide treatment for patients with hard-to-treat biliary tract cancers; and uses artificial intelligence (AI) to study early development.
Scanning electron microscope image of a breast cancer cell.
In the Lab
Mutations in the Same Gene Create Different Paths to Breast Cancer Drug Resistance

A new finding provides insight into how breast cancer develops resistance to aromatase inhibitors.
MSK Researchers Identify First Evidence of Epigenetic Role in Breast Cancer

Researchers at Memorial Sloan Kettering Cancer Center have identified, for the first time, an epigenetic mechanism promoting breast cancer. The team found that inhibition of the PI3K pathway leads to activation of ER-dependent transcription through the epigenetic regulator KMT2D. These findings provide a rationale for epigenetic therapy in patients with PIK3CA-mutant, ER-positive breast cancer. While epigenetic factors have been known to play an important role in various cancers such as leukemia and lymphoma, this is the first evidence found in breast cancer. This research co-led by José Baselga, MD, PhD, Physician-in-Chief and Chief Medical Officer, appears in the March 24, 2017 issue of Science. For more information on this work and to speak with the study authors, contact [email protected].
Female doctor in white coat examining patient with stethoscope.
Feature
Shorter, Safer, Smarter: How MSK Enhances Radiation Therapy for Breast Cancer

MSK leads the way in optimizing radiation treatment for breast cancer patients.
Sarah smiles in front of an MSK sign
How Genetic Cascade Testing Can Break the Cycle of Inherited Cancer Risk

Learn how the diagnosis of an inherited BRCA1 mutation is helping one family reduce its cancer risk.
Surgeon in scrubs operating on patient.
In the Clinic
Study Findings Could Help Women Make Decisions about Breast Cancer Surgery

Women who have reconstructive surgery after mastectomy and radiation for breast cancer are usually more satisfied with the results when their own tissue is used instead of implants.